



Advancing Research. Improving Lives.™

TO: ALL PRINCIPAL INVESTIGATORS, NURSES AND DATA MANAGERS

FROM: Protocol Development and Regulatory Compliance

DATE: October 8, 2024

RE: PROTOCOL NRG-LU004 – TEMPORARILY SUSPENDED TO ACCRUAL

Effective immediately, NRG-LU004, “Phase I Trial of Radiotherapy Combined With Durvalumab Alone Plus Either Monalizumab or Oleclumab in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1),” is suspended to accrual to allow NRG Oncology to evaluate the current treatment landscape for patients with PDL-1 high locally advanced disease.

There are no patient safety issues related to the accrual suspension, and no patients have been enrolled to the study since its reopening in January 2024.

Please distribute this information to the appropriate personnel at participating affiliate institutions.